NuCana (NCNA) Share-based Compensation (2017 - 2025)
NuCana (NCNA) reported Share-based Compensation of $1.2 million for Q4 2025, up 4467.5% on a YoY basis from $25773.3 in Q4 2024, and down 2.63% sequentially from $1.2 million in Q3 2025.
NuCana (NCNA) Share-based Compensation (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Share-based Compensation data on file, last reported at $1.2 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 4467.5% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 35.87% YoY), and the FY2025 full-year result was $13.2 million, up 528.41% from the prior year.
- Share-based Compensation retreated to $1.2 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2021 to a low of -$26953.5 in Q4 2024.
- A 5-year average of $1.4 million and a median of $1.3 million in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation slumped 102.77% in 2024 and jumped 4467.5% in 2025, its largest moves.
- Tracing NCNA's Share-based Compensation over 5 years: stood at $2.4 million in 2021, then tumbled by 37.58% to $1.5 million in 2022, then plunged by 33.73% to $973063.1 in 2023, then tumbled by 102.77% to -$26953.5 in 2024, then jumped by 4467.5% to $1.2 million in 2025.
- Business Quant data shows NCNA's Share-based Compensation at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and -$26953.5 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.18 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | -26,953.54 |
| Dec 31, 2024 | -26,953.54 |
| Sep 30, 2024 | 487,237.56 |
| Sep 30, 2024 | 487,237.56 |
| Jun 30, 2024 | 840,639.02 |
| Jun 30, 2024 | 840,639.02 |
| Mar 31, 2024 | 794,092.38 |
| Mar 31, 2024 | 794,092.38 |
| Dec 31, 2023 | 973,063.08 |
| Dec 31, 2023 | 973,063.08 |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.39 Mn |